Refine by
Microbiome Research Discovery Articles & Analysis
47 news found
"We are thrilled to introduce Long Amplicon Analysis to the genomics research community," stated the Market Director of CD Genomics. "LAA breaks through traditional sequencing constraints, empowering researchers with invaluable insights into the most intricate areas of the genome, accelerating their research and making significant contributions ...
The product manager is pleased to announce the launch of its Microbial Biomarker Discovery service, a revolutionary solution that promises to transform microbiology research. Microbiome research has rapidly gained momentum in recent years as scientists have come to appreciate the vital role that microbial communities play in ...
Bened Biomedical Co, LTD., the global leader in psychobiotics with clinical studies, has acquired its US distributor Oryx Biomedical, Inc., who is pioneering the translation of microbiome research into impactful biotherapeutics and is one of the earliest stage companies bringing the gut-brain axis category of probiotics to the market. Based in Taiwan and founded by Prof. Ying-Chieh Tsai, PhD, ...
It brings our legacy of expertise in Nebraska, which is focused on discovery, to the next level. We are investing in the next phase of microbiome health: post-discovery development and commercialization that will efficiently bring products to ...
Funds to support scale-up, including continued development of AI-augmented knowledge discovery platform, the e[datascientist]™, and continued international expansion Platform business focused on bridging the current ‘translation gap’, addressing critical bottlenecks in the industrial application of microbiome science – from soil, to plant, to farm, to fork, to human, ...
Today, Eagle Genomics, the software platform business pioneering the application of network science to biology,?announced its attendance at international tradeshow ACHEMA 2022 in Frankfurt, Germany next week (22-26 August) as a Microsoft Showcase Partner. Eagle Genomics will be featured in Microsoft’s ‘Digital Hub’ Innovation space under the theme “Eagle Genomics and ...
A surge in research projects on the human microbiome - the complex ecosystem of microorganisms in the human gastrointestinal tract - is bolstering scientific understanding of health, disease and environment. Much of the research has focused on gut bacteria and viruses, leaving a third factor - fungi - little studied. An international consortium of scientists has conducted the first large-scale ...
The Microbiome Therapeutics Innovation Group (MTIG) today announced the addition of Bio-Me to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products. Bio-Me offers a wide range of proprietary solutions to facilitate the gut microbiome analysis process for academia and pharma researchers and is setting the ...
ByBio-Me
v=V3SjGS8Pb4k About Aptorum Group Limited Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline of ...
The project, to support the ongoing development of Microbiotica’s Live Bacterial Therapeutic (LBT) MB310 for the treatment of ulcerative colitis (UC), was funded following an extensive review process including industrial and clinical key opinion leaders, and is strong recognition of Microbiotica’s unique capabilities in the discovery and development of ...
Microviable Therapeutics SL (Gijón, Asturias, Spain), announced a contractual agreement with BCD Bioscience Inc. (California, USA) to work on microbial fermentation and novel prebiotics to modulate the human gut microbiome. Microviable expertise on gut microbiome research will enable to conveniently process microbiota samples for fermentation applications that coupled with BCD ...
Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, today announced the completion of a £50 million ($67 million) Series B financing round – the largest microbiome-related financing in Europe to date. ...
City of Hope, one of the largest cancer research and treatment organizations in the United States, and Osel Inc., a company developing live biotherapeutic products for modulation of the human microbiome, today announced Phase 1 trial data showing that use of the live biotherapeutic CBM588 (Clostridium butyricum MIYAIRI 588® strain) plus immunotherapy medicine nivolumab/ipilimumab ...
Microbiome-based ingredient company Synbiotic Health announces that Kevin Hooper has joined the company as Director of Business Development. Hooper has more than 14 years’ experience in sales and business development, most recently at the global ingredient supplier IFF Health. At Synbiotic Health he will work with Steve Prescott, Senior Vice President of Business Development, to implement ...
Microbiome-based ingredient company Synbiotic Health is pleased to announce the appointment of Erin Vyhlidal as Controller and Vice President, Corporate Finance. Vyhlidal is a CPA (inactive registrant) with twenty years’ experience in accounting. She previously oversaw a team of nine as VP Corporate Finance at Farmers National Company in Omaha, NE, after working at PricewaterhouseCoopers as ...
CD Genomics is a leading services company committed to providing global customers with the most comprehensive analytic services, including a broad range of microbial genomic solutions to support research and development. The company announced microbiome profiling services, alongside bioinformatic analysis technology to help researchers understand ...
The pivotal Phase 3 program builds on nearly a decade of research with robust clinical and microbiome data collected over six controlled clinical trials with more than 1,000 participants. ...
The SMRT-based transcriptomics platform provides a simple and accurate method for various applications, such as gene annotation, identification of transcript isoforms and fusion transcripts, long non-coding RNA (lncRNA) discovery, microRNA (miRNA) discovery, and prediction of potential mRNA target molecules. ...
The pivotal Phase 3 program builds on nearly a decade of research with robust clinical and microbiome data collected over six controlled clinical trials with more than 1,000 participants. ...
On September 22nd Warren Flood, Ph.D. and COO of Bio-Me, will participate in a webinar organized together with Thermo Fisher Scientific with the title “Missing a piece of the puzzle? Factor in the gut microbiome”. There, he will present how our PMP platform, based on Thermo Fisher Scientific’s OpenArray qPCR technology, helps researchers and ...
ByBio-Me